SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Severin F. F.)
 

Search: WFRF:(Severin F. F.) > Clinical outcome en...

  • Zannad, F.Université de Lorraine, Nancy, France (author)

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2014-01-27
  • Wiley,2013

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/180384
  • https://gup.ub.gu.se/publication/180384URI
  • https://doi.org/10.1093/eurjhf/hft095DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-99814URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g. all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 12-13 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the group's recommendations for achieving common views on heart failure endpoints in clinical trials.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Garcia, A. A.European Medicines Agency, Madrid, Spain (author)
  • Anker, S. D.Charité Medical School, Berlin, Germany,Brigham and Women's Hospital, Boston, MA, USA (author)
  • Armstrong, P. W.University of Alberta, Edmonton, Canada,Medical University, Military Hospital, Wroclaw, Poland (author)
  • Calvo, G.Hospital Clinic of Barcelona, Spain (author)
  • Cleland, J. G.Castle Hill Hospital, Kingston-upon-Hull, UK (author)
  • Cohn, J. N.University of Minnesota, Minneapolis, USA (author)
  • Dickstein, K.University of Bergen, Stavanger University Hospital, Norway (author)
  • Domanski, M. J.Mount Sinai School of Medicine, New York, USA,University of Brescia, Italy (author)
  • Ekman, Inger,1952Gothenburg University,Göteborgs universitet,Centrum för personcentrerad vård vid Göteborgs universitet (GPCC),University of Gothenburg Centre for person-centred care (GPCC),Sahlgrenska Academy, Gothenburg University, Sweden(Swepub:gu)xekmin (author)
  • Filippatos, G. S.Athens University Hospital Attikon, Greece (author)
  • Gheorghiade, M.Northwestern University Feinberg School of Medicine, Chicago, IL, USA (author)
  • Hernandez, A. F.Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA (author)
  • Jaarsma, TinyLinköpings universitet,Hälsa, Aktivitet, Vård (HAV),Hälsouniversitetet(Swepub:liu)tinja77 (author)
  • Koglin, J.Merck, Sharpe & Dohme Corporation, Whitehouse Station, NJ, USA (author)
  • Konstam, M.Tufts University, Boston, MA, USA (author)
  • Kupfer, S.Takeda Pharmaceuticals, Deerfield, IL, USA (author)
  • Maggioni, A. P.ANMCO Research Center, Florence, Italy (author)
  • Mebazaa, A.Hopital Lariboisiere, Paris, France (author)
  • Metra, M.Hospital 12 de Octubre, Madrid, Spain,Amgen Inc., Thousand Oaks, CA, USA (author)
  • Nowack, C.Bayer Pharma AG, Wuppertal, Germany (author)
  • Pieske, B.Medical University of Graz, Austria (author)
  • Pina, I. L.Montefiore Medical Center, Bronx, NY, USA (author)
  • Pocock, S. J.London School of Hygiene and Tropical Medicine, UK (author)
  • Ponikowski, P. (author)
  • Rosano, G.IRCCS San Raffaele Hospital, Rome, Italy (author)
  • Ruilope, L. M. (author)
  • Ruschitzka, F.University Hospital Zurich, Switzerland (author)
  • Severin, T.Novartis Pharma AG, Basel, Switzerland (author)
  • Solomon, S. (author)
  • Stein, K.Boston Scientific Corporation, St. Paul, MN, USA (author)
  • Stockbridge, N. L.Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (author)
  • Stough, W. G.Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA (author)
  • Swedberg, Karl,1944Sahgrenska University, Hospital/Östra, Göteborg, Sweden(Swepub:gu)xsweka (author)
  • Tavazzi, L.Villa Maria Cecilia Hospital, Cotignola, Italy (author)
  • Voors, A. A.University Medical Center, Groningen, The Netherlands (author)
  • Wasserman, S. M. (author)
  • Woehrle, H.ResMed, Ulm, Germany (author)
  • Zalewski, A.Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (author)
  • McMurray, J. J.University of Glasgow, UK (author)
  • Université de Lorraine, Nancy, FranceEuropean Medicines Agency, Madrid, Spain (creator_code:org_t)

Related titles

  • In:European Journal of Heart Failure: Wiley15:10, s. 1082-10941388-98421879-0844

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view